Biologically Active Small Molecules

An inhibitor of SRE activation in PC3 cells (IC₅₀ = 6.4 &muM), with 87% inhibition of SRE activation achieved at 100 &muM inhibits PC3 cell migration (IC₅₀ = 4.

An inhibitor of SRE activation in PC3 cells (IC₅₀ = 6.4 &muM), with 87% inhibition of SRE activation achieved at 100 &muM inhibits PC3 cell migration (IC₅₀ = 4.

An inhibitor of RGS4 (IC50 = 30 nM) blocks GTPase activity and G&alpha0-dependent translocation of RGS4 to the membrane.

An inhibitor of RGS4 (IC50 = 30 nM) blocks GTPase activity and G&alpha0-dependent translocation of RGS4 to the membrane.

An inhibitor of RGS4 (IC50 = 30 nM) blocks GTPase activity and G&alpha0-dependent translocation of RGS4 to the membrane.

A 3,4-diaryl pyrazoloresorcinol compound that inhibits the Hsp90 ATPase activity with IC50 values of 3.2 and 6.

A 3,4-diaryl pyrazoloresorcinol compound that inhibits the Hsp90 ATPase activity with IC50 values of 3.2 and 6.

A 3,4-diaryl pyrazoloresorcinol compound that inhibits the Hsp90 ATPase activity with IC50 values of 3.2 and 6.

An ATP-competitive inhibitor of Akt2 (IC₅₀ = 6 nM) blocks the phosphorylation of Akt targets, inhibits proliferation of multiple tumor cell lines in vitro, and prevents the growth of human tumor xenografts in mice.

An ATP-competitive inhibitor of Akt2 (IC₅₀ = 6 nM) blocks the phosphorylation of Akt targets, inhibits proliferation of multiple tumor cell lines in vitro, and prevents the growth of human tumor xenografts in mice.

An ATP-competitive inhibitor of Akt2 (IC₅₀ = 6 nM) blocks the phosphorylation of Akt targets, inhibits proliferation of multiple tumor cell lines in vitro, and prevents the growth of human tumor xenografts in mice.

An ATP-competitive inhibitor of Akt2 (IC₅₀ = 6 nM) blocks the phosphorylation of Akt targets, inhibits proliferation of multiple tumor cell lines in vitro, and prevents the growth of human tumor xenografts in mice.